Peptide questions · Petrelintide
Petrelintide side effects: what studies and users report
Reviewed Evidence: ModeratePublished by PepVault
The side effects most commonly reported for petrelintide are nausea, decreased appetite and constipation, among 4 the library lists; the library’s evidence on it includes controlled trials in people.
Its safety note opens: petrelintide has no label: it is still in trials.
What is commonly reported with petrelintide
- Nausea
- Decreased appetite
- Constipation
- Diarrhea
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 24) |
|---|---|
| Nausea | 21: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 17 more |
| Decreased appetite | 9: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 5 more |
| Constipation | 13: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 9 more |
| Diarrhea | 20: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 16 more |

Model. Individual results vary.
Which petrelintide side effects the metabolic & GLP-1 group shares
Across the 25 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (22 of 25), diarrhea (21 of 25), vomiting (19 of 25) and constipation (14 of 25). Every effect on petrelintide’s list also appears for at least one other metabolic & GLP-1 compound, so nothing on it is petrelintide’s own.
What the petrelintide safety notes say
The library’s safety note
Petrelintide has no label: it is still in trials. In the 42-week ZUPREME-1 trial, the most common side effect was nausea (20% vs 6% on placebo), mostly mild and during the step-ups; vomiting (3% vs 6%), diarrhea (7% vs 7%) and constipation (7% vs 4%) were about as common as on placebo, and there were no deaths. In the diabetes trial, 1.9% stopped for GI side effects vs 1.7% on placebo. Long-term safety is not yet known. These are trial findings to review with your clinician.
The library’s interaction note
No interaction studies have been published. Amylin can slow stomach emptying, which could change how quickly oral medicines are absorbed. It is not a GLP-1; beside one, the GI side effects can add up, and the pair has not yet been tested in a published trial. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the petrelintide reports come from
The library rates the evidence on petrelintide as moderate: animal studies plus some human data.
Of the library’s 8 research notes on petrelintide, 6 rest on randomized trials, 1 on clinical data and 1 on community reports.
Our 1 study page on petrelintide: 1 randomized trial.
So petrelintide has controlled trials in people to set its listed effects against.
What our petrelintide study pages report on safety
Petrelintide: up to 8.6% weight loss at 16 weeks in phase 1
Randomized trial, human, 2026: No one had a serious or severe side effect, and the most common ones were stomach and gut problems, mostly mild. In part 2 of the repeated-dose trial, nausea occurred in 16.7%-33.3% of people on petrelintide versus 16.7% on placebo; diarrhea was rare, and only one person vomited, the same person who stopped treatment because of gut side effects.
Questions people ask
What are the side effects of petrelintide?
The side effects most commonly reported for petrelintide are nausea, decreased appetite and constipation, among 4 the library lists; the library’s evidence on it includes controlled trials in people.
Do petrelintide’s side effects come from human studies?
The library rates the evidence on petrelintide as moderate, and the library’s evidence on it includes controlled trials in people.
Which petrelintide side effects are its own?
None: each effect the library lists for petrelintide is listed for at least one other metabolic & GLP-1 compound too.
Does petrelintide interact with other medicines?
The library’s interaction note on petrelintide begins: No interaction studies have been published.